CCL2 and type 2 diabetes mellitus: One clinical study designed to investigate the effects of baricitinib in patients with T2DM showed that treatment with baricitinib in combination with RAAS inhibitors improved albuminuria and reduced inflammatory biomarkers, such as serum TNF receptor 1, TNF receptor 2, and urinary CCL2 [172].